VOR Vor Biopharma Inc.
$19.54▲ +6.60%
Healthcare
Other
After hours
$19.90▲ +1.84%
Oct 27, 5:17 PM ET
Volume 769.9K
Avg Volume (10D) 755.8K
Key Metrics & Fundamentals
Market Cap
$1.16B
P/E Ratio
0.1
Div Yield
0.00%
52W Range
6.50 - 28.66
% vs 50 MA
-6.60%
% vs 200 MA
13.33%
RSI-14
51.1
MACD Histogram
+0.1500
Beta (1Y vs SPY)
1.72
Free Cash Flow
-$25.50M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$28.52M
COGS
–
Operating Exp
$47.85M
Operating Income
-$47.85M
EBIT
-$47.85M
Pretax Income
-$62.81M
Net Income
-$62.81M
EPS (Diluted)
-1.16
Price & Volume History
Loading chart…
Recent News
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
GlobeNewswire · Oct 22, 2026 4:05 PM ET
William Blair Initiates Vor Biopharma at Outperform
MT Newswires · Oct 21, 2026 7:42 AM ET
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
Simply Wall St. · Oct 8, 2026 11:17 AM ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 5, 2026 6:00 PM ET
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
Simply Wall St. · Oct 4, 2026 12:05 PM ET
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
GlobeNewswire · Sep 29, 2026 8:05 AM ET
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
PR Newswire · Sep 16, 2026 10:31 AM ET
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
MT Newswires · Sep 8, 2026 7:46 AM ET
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
GlobeNewswire · Sep 8, 2026 7:00 AM ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 4, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See VOR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.